Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group
Pfrepper, C.; Klamroth, R.; Oldenburg, J.; Holstein, K.; Eichler, H.; Hart, C.; Moehnle, P.; Schilling, K.; Trautmann-Grill, K.; Alrifai, M.; Ay, C.; Miesbach, W.; Knoebl, P.; Tiede, A. · Zeitschrift für Orthopädie und Unfallchirurgie · 2024 · Heft 06 · S. 466 bis 471
Bibliografische Angaben
Zusammenfassung
Abstract Background Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Standard treatment consists of bleeding control with bypassing agents and immunosuppressive therapy. Emicizumab is a bispecific antibody that mimics the function of activated FVIII irrespective of the presence of neutralizing antibodies. Recently, the GTH-AHA-EMI study demonstrated that emicizumab prevents bleeds and allows to postpone immunosuppression, which may influence future treatment strategies. Aim To provide clinical practice recommendations on the use of emiciz…
